90 related articles for article (PubMed ID: 20626045)
1. Divergent expression of CD133 in different studies: the need for a consensus panel?
Sgambato A; Errico F; Caredda E; Puglisi MA; Cittadini A
Int J Cancer; 2011 May; 128(9):2247-9. PubMed ID: 20626045
[No Abstract] [Full Text] [Related]
2. Flow cytometric characterization of the DAOY medulloblastoma cell line for the cancer stem-like phenotype.
Srivastava VK; Nalbantoglu J
Cytometry A; 2008 Oct; 73(10):940-8. PubMed ID: 18773455
[TBL] [Abstract][Full Text] [Related]
3. [Investigation of CD133 as putative marker of tumor-initiating cell in laryngeal carcinoma].
Wei XD; Zhou L; Cheng L; Tian J
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 Sep; 42(9):692-6. PubMed ID: 18051573
[TBL] [Abstract][Full Text] [Related]
4. Isolation and partial characterization of a new human glioblastoma cell line.
Brehar FM; Bleotu C; Stefan LM; Buzgariu W; Chivu M; Utoiu E; Matei L; Ciurea AV; Tascu A
Chirurgia (Bucur); 2009; 104(4):453-61. PubMed ID: 19886054
[TBL] [Abstract][Full Text] [Related]
5. CD133 and ABCB5 as stem cell markers on sentinel lymph node from melanoma patients.
Gazzaniga P; Cigna E; Panasiti V; Devirgiliis V; Bottoni U; Vincenzi B; Nicolazzo C; Petracca A; Gradilone A
Eur J Surg Oncol; 2010 Dec; 36(12):1211-4. PubMed ID: 20573479
[No Abstract] [Full Text] [Related]
6. The first extracellular domain of the tumour stem cell marker CD133 contains an antigenic ganglioside-binding motif.
Taïeb N; Maresca M; Guo XJ; Garmy N; Fantini J; Yahi N
Cancer Lett; 2009 Jun; 278(2):164-173. PubMed ID: 19216024
[TBL] [Abstract][Full Text] [Related]
7. Melanoma stem cells: the dark seed of melanoma.
Zabierowski SE; Herlyn M
J Clin Oncol; 2008 Jun; 26(17):2890-4. PubMed ID: 18539969
[TBL] [Abstract][Full Text] [Related]
8. [Study on culture, identification and differentiation of CD133+ endothelial progenitor cells from human umbilical cord blood].
Huang Y; Wang SM; Wang JS; Huang XL
Zhonghua Wai Ke Za Zhi; 2007 May; 45(9):619-22. PubMed ID: 17688798
[TBL] [Abstract][Full Text] [Related]
9. Expression of haematopoietic stem cell markers, CD133 and CD34 on human corneal keratocytes.
Perrella G; Brusini P; Spelat R; Hossain P; Hopkinson A; Dua HS
Br J Ophthalmol; 2007 Jan; 91(1):94-9. PubMed ID: 16956910
[TBL] [Abstract][Full Text] [Related]
10. Elevated tissue factor procoagulant activity in CD133-positive cancer cells.
Milsom C; Anderson GM; Weitz JI; Rak J
J Thromb Haemost; 2007 Dec; 5(12):2550-2. PubMed ID: 17883595
[No Abstract] [Full Text] [Related]
11. CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell lines HCT-116.
Dittfeld C; Dietrich A; Peickert S; Hering S; Baumann M; Grade M; Ried T; Kunz-Schughart LA
Radiother Oncol; 2009 Sep; 92(3):353-61. PubMed ID: 19699546
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic significance of putative stem cell marker, CD44 and CD133, in human gastric carcinoma.
Chen S; Hou JH; Feng XY; Zhang XS; Zhou ZW; Yun JP; Chen YB; Cai MY
J Surg Oncol; 2013 Jun; 107(8):799-806. PubMed ID: 23609373
[TBL] [Abstract][Full Text] [Related]
13. Investigation of diagnostic utility and expression profiles of stem cell markers (CD133 and CD90) in hepatocellular carcinoma, small cell dysplasia, and cirrhosis.
Yilmaz G; Akyol G; Cakir A; Ilhan M
Pathol Res Pract; 2014 Jul; 210(7):419-25. PubMed ID: 24702884
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma.
Xi HQ; Zhao P
J Clin Pathol; 2011 Jun; 64(6):498-503. PubMed ID: 21415057
[TBL] [Abstract][Full Text] [Related]
15. CD133 is a selective marker of CRC?
Del Rio P; Bonati E; Crafa P; Campanini N; Montana Montana C; Bezer L; Dell'Abate P; Sianesi M
Minerva Chir; 2013 Feb; 68(1):87-95. PubMed ID: 23584268
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of the Stem Cell Markers Epcam and CD133 Expression Of Gallbladder Adenocarcinoma.
Jiang S; Pei L; Yang ZL; Liu G
Hepatogastroenterology; 2014 May; 61(131):574-9. PubMed ID: 26176038
[TBL] [Abstract][Full Text] [Related]
17. How powerful is CD133 as a cancer stem cell marker in brain tumors?
Cheng JX; Liu BL; Zhang X
Cancer Treat Rev; 2009 Aug; 35(5):403-8. PubMed ID: 19369008
[TBL] [Abstract][Full Text] [Related]
18. Establishment of a highly migratory subclone reveals that CD133 contributes to migration and invasion through epithelial-mesenchymal transition in pancreatic cancer.
Ding Q; Yoshimitsu M; Kuwahata T; Maeda K; Hayashi T; Obara T; Miyazaki Y; Matsubara S; Natsugoe S; Takao S
Hum Cell; 2012 Mar; 25(1):1-8. PubMed ID: 22109279
[TBL] [Abstract][Full Text] [Related]
19. CD133 expression is correlated with poor prognosis in colorectal cancer.
Kashihara H; Shimada M; Kurita N; Iwata T; Sato H; Kozo Yoshikawa ; Higashijima J; Chikakiyo M; Nishi M; Matsumoto N
Hepatogastroenterology; 2014 Sep; 61(134):1563-7. PubMed ID: 25436343
[TBL] [Abstract][Full Text] [Related]
20. Differentiation of CD133-positive pancreatic cells into insulin-producing islet-like cell clusters.
Koblas T; Pektorova L; Zacharovova K; Berkova Z; Girman P; Dovolilova E; Karasova L; Saudek F
Transplant Proc; 2008 Mar; 40(2):415-8. PubMed ID: 18374086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
